换一批
换一批Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL).
作者：
主题词
青少年(Adolescent);成年人(Adult);老年人(Aged);抗体, 单克隆(Antibodies, Monoclonal);抗体, 单克隆, 鼠源性(Antibodies, Monoclonal, Murine-Derived);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);顺铂(Cisplatin);综合疗法(Combined Modality Therapy);脱氧胞苷(Deoxycytidine);无病生存(Disease-Free Survival);药物评价(Drug Evaluation);女(雌)性(Female);人类(Humans);免疫疗法(Immunotherapy);Kaplan-Meiers评估(Kaplan-Meier Estimate);淋巴瘤, 大B细胞, 弥漫性(Lymphoma, Large B-Cell, Diffuse);男(雄)性(Male);甲泼尼龙(Methylprednisolone);中年人(Middle Aged);外周血干细胞移植(Peripheral Blood Stem Cell Transplantation);放射疗法, 辅助(Radiotherapy, Adjuvant);缓解诱导(Remission Induction);回顾性研究(Retrospective Studies);挽救疗法(Salvage Therapy);存活率分析(Survival Analysis);存活率(Survival Rate);治疗结果(Treatment Outcome)
DOI
10.1080/10245330701214095
PMID
17454196
发布时间
2022-12-07
- 浏览2
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
